Cardiac effects of amiselimod compared with fingolimod and placebo: results of a randomised, parallel‐group, phase I study in healthy subjects-Reference-Cited by-同舟云学术

Cardiac effects of amiselimod compared with fingolimod and placebo: results of a randomised, parallel‐group, phase I study in healthy subjects

Author:

Harada Tomohiko¹,Wilbraham Darren¹,La Borderie Guillemette¹,Inoue Shinsuke²,Bush Jim³,Camm A. John⁴

Affiliation:

1. Mitsubishi Tanabe Pharma Europe Ltd. Dashwood House, 69 Old Broad Street London EC2M 1QS UK

2. Mitsubishi Tanabe Pharma Corporation 17‐10, Nihonbashi‐Koamicho, Chuo‐ku Tokyo 103‐8405 Japan

3. Principal Investigator, Covance CRU Ltd. Springfield House, Hyde Street Leeds LS2 9LH UK

4. Cardiovascular and Cell Sciences Research InstituteSt. George's University of London London SW17 0RE UK

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

Reference33 articles.

4. Gilenya: summary of product characteristics [online]. Available athttp://www.medicines.org.uk/emc/medicine/24443(last accessed 2 December 2016).

5. Role of sphingosine 1‐phosphate receptor type 1 in lymphocyte egress from secondary lymphoid tissues and thymus;Chiba K;Cell Mol Immunol,2006

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献